Sanofi's $2.5 billion acquisition of immuno-oncology company Synthorx Inc. received antitrust clearance.

The Paris-based drugmaker said the waiting period under the Hart-Scott-Rodino Act applicable to the deal has expired.

On Dec. 23, 2019, Sanofi started a tender offer to acquire all of Synthorx's shares at $68 each.

La Jolla, Calif.-based Synthorx is developing therapies intended to treat cancer and autoimmune disorders through its proprietary technology. The company's lead asset, THOR-707, is being evaluated as a potential treatment of multiple solid tumor types as a stand-alone therapy and in combination with immune checkpoint inhibitors.